Viral infections in the context of "Kanamycin"

Play Trivia Questions online!

 or

Skip to study material about Viral infections in the context of "Kanamycin"
Ad spacer

>>>PUT SHARE BUTTONS HERE<<<

👉 Viral infections in the context of Kanamycin

Kanamycin A, often referred to simply as kanamycin, is an antibiotic used to treat severe bacterial infections and tuberculosis. It is not a first line treatment. It is used by mouth, injection into a vein, or injection into a muscle. Kanamycin is recommended for short-term use only, usually from 7 to 10 days. Since antibiotics only show activity against bacteria, it is ineffective in viral infections.

Common side effects include hearing and balance problems. Kidney problems may also occur. Kanamycin is not recommended during pregnancy as it may harm the baby. It is likely safe during breastfeeding. Kanamycin is in the aminoglycoside family of medications. It has the weakest antibacterial capabilities of all compounds in this family when used clinically, which is partially due to its increased toxicity in comparison to other aminoglycosides. It works by blocking the production of proteins that are required for bacterial survival.

↓ Explore More Topics
In this Dossier

Viral infections in the context of Therapeutic vaccines

A therapeutic vaccine is a vaccine which is administered after a disease or infection has already occurred. A therapeutic vaccine works by activating the immune system of a patient to fight an infection. A therapeutic vaccine differs from a prophylactic vaccine in that prophylactic vaccines are administered to individuals as a precautionary measure to avoid the infection or disease while therapeutic vaccines are administered after the individual is already affected by the disease or infection.A therapeutic vaccine fights an existing infection in the body rather than immunizing the body for protection against future diseases and infections.Therapeutic vaccines are mostly used against viral infections. Patients affected with chronic viral infections are administered with therapeutic vaccines, as their immune system is not able to produce enough efficient antibodies.

Provenge, developed by Dendreon, was the first therapeutic vaccine approved by the FDA in 2010. This therapeutic vaccine helped in treating prostate cancer where patients' own white blood cells (WBCs) were taken and treated with drug (vaccine) to train them to differentiate and fight cancer cells.

↑ Return to Menu
LINKED FROM (PARENTS)
← Therapeutic vaccines ← Kanamycin ← Kanamycin A
LINKS TO (CHILDREN)